GSK958108

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Premature Ejaculation

Phase 1

FTIH Study With GSK958108

CompletedNCT00664365

GlaxoSmithKlinePremature Ejaculation

Start: 2008-04-12End: 2008-08-22Updated: 2017-08-01

Proof of Mechanism in ELT

CompletedNCT00861484

GlaxoSmithKlinePremature Ejaculation

Start: 2008-11-26End: 2009-12-11Updated: 2017-06-14

Related Papers

A Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of a Single Oral Dose of 5-HT1A Antagonist GSK958108 on Ejaculation Latency Time in Male Patients Suffering From Premature Ejaculation

The Journal of Sexual Medicine2020-11-209 citations

PD28-08 A DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF A SINGLE ORAL DOSE OF GSK958108 ON EJACULATION LATENCY TIME IN MALE PATIENTS SUFFERING FROM PREMATURE EJACULATION

The Journal of Urology2019-04-012 citations